Intrapleural BCG in postsurgical stage I non-small cell lung cancer.
In a randomized trial comparing intrapleural bacillus Calmette-Guérin (BCG) with placebo in postsurgical stage I non-small cell lung cancer, BCG-treated patients (n = 17) showed a non-significant overall improvement of 5-year and median survival and disease-free interval, but an increased rate of recurrence of cancer compared with control patients (n = 17).
Macchiarini
P
P
Service of Thoracic Surgery, University of Pisa, Italy.
Mussi
A
A
Angeletti
C A
CA
D000276:Adjuvants, Immunologic; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009163:Mycobacterium bovis / Q000276:immunology*
D000276:Adjuvants, Immunologic